• Welcome to Specialised Therapeutics
  • SE Asia (HQ)

    +65 3158 9910

  • Australia

    1300 798 820

  • New Zealand

    +64 9801 0299

May 2017 - ST acquires rights to anti-cancer compound ZEPZELCA® (lurbinectedin)

ST signs a second major licensing deal with European pharmaceutical company PharmaMar.